Search the Newsreel

Adapthealth Corp (AHCO) Cash Flow

This article provides a detailed cash flow statement for Adapthealth Corp (AHCO), presenting quarterly and annual figures for operating, investing, and financing activities. It also includes frequently asked questions explaining different types of cash flow and how Adapthealth Corp has performed in each category. …

Adaptive Biotechnologies Corp (ADPT) Financial Health: Profitability & Balance Sheet Analysis

Adaptive Biotechnologies Corp (ADPT) has a current financial score of 7.62, ranking 97 out of 386 in the Biotechnology & Medical Research industry, indicating a weak financial status but high operating efficiency. The company reported a quarterly revenue of $70.87 million, marking a 35.14% …

Adaptive Biotechnologies Corp (ADPT) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Adaptive Biotechnologies Corp (ADPT), listing its major shareholders and their respective proportions, with Viking Global Investors LP holding the largest share. It also categorizes shareholders by type and provides a historical overview of institutional shareholding and recent …

Adaptive Biotechnologies Corp (ADPT) Cash Flow

This article provides a comprehensive overview of Adaptive Biotechnologies Corp (ADPT)'s cash flow statements, including operating, investing, and financing activities. It presents detailed quarterly and annual financial data, highlighting key metrics like operating cash flow, capital expenditures, and free cash flow. The article also …

AHCO|Adapthealth Corp|Price:10.989|Chg%:+0.229

This article provides a detailed company profile for Adapthealth Corp (AHCO), a provider of home medical equipment and services. It includes information on the company's business scope, key financial data, and market performance, along with a list of company executives and major shareholders. The …

Adaptive Biotechnologies Corp (ADPT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution — TradingKey

This article provides a revenue breakdown for Adaptive Biotechnologies Corp (ADPT), detailing its financial performance by business segments. It shows that MRD revenue accounts for 76.66% ($212.33M) and Immune medicine revenue for 23.34% ($64.64M). The article also indicates the current stock price and market …

Indaptus Therapeutics Market Sentiment

The article provides a market sentiment analysis for Indaptus Therapeutics (INDP), highlighting analyst consensus, short interest, options flow, and insider activity. Analysts have a "Buy" consensus with an average price target significantly above the current stock price. Recent insider activity shows notable investments and …

Indaptus Therapeutics Inc (INDP) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides a historical overview of dividend payouts and stock splits for Indaptus Therapeutics Inc (INDP). It notes that the company has not distributed any dividends in the past five years. The article details several stock merger events with varying ratios, primarily from …

Adaptive Biotechnologies Corp (ADPT) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Adaptive Biotechnologies Corp (ADPT), highlighting its current earnings forecast score, average price target, and analyst ratings. It includes peer comparisons and answers frequently asked questions regarding revenue expectations, price targets, and past EPS performance. The consensus among …

Danaher Aktie: 1,94 Dollar EPS schlägt Erwartung

ADPT|Adaptive Biotechnologies Corp|Price:24.455|Chg%:-0.795

Adaptive Biotechnologies Corp (ADPT) is a commercial-stage biotechnology company focused on harnessing the adaptive immune system for disease diagnosis and treatment. The company's fundamentals are stable with high growth potential, and its valuation is considered fairly valued within the Biotechnology & Medical Research industry. …

ADPT|Adaptive Biotechnologies Corp|Price:22.270|Chg%:-0.040

Adaptive Biotechnologies Corp (ADPT) is a commercial-stage biotechnology company focused on harnessing the adaptive immune system for disease diagnosis and treatment. The company's fundamentals are stable with high growth potential, and its valuation is considered fairly valued within the Biotechnology & Medical Research industry. …

Danaher (DHR) Could Be 16% Undervalued On Earnings And 2026 Revenue Guidance

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Danaher (DHR) has attracted investor attention after issuing third quarter 2026 revenue guidance of 2% to 3% growth, alongside detailing recent share repurchases …

Indaptus Therapeutics Inc (INDP) Institutional Confidence

This article from TradingKey provides an overview of institutional confidence in Indaptus Therapeutics Inc (INDP). It lists key shareholders and their activity, including changes in shares held. The data focuses on individual and institutional shareholding as of July 24, 2026.

Do Weakening Returns on Capital Hint at Deeper Strategy Questions for AdaptHealth (AHCO)?

AdaptHealth (AHCO) is facing operational strains with flat sales, falling earnings per share, and weakening returns on capital, complicating its investment narrative despite increased revenue guidance. These trends suggest that future growth relies less on revenue beats and more on new investments boosting margins …

Adaptive Biotechnologies Corp. Revenue Breakdown – HAM:1HM

Adaptive Biotechnologies Corp. (HAM:1HM) generated €235.82 million in revenue last year, primarily from its Minimal Residual Disease - Service segment, which contributed €164.18 million. The majority of its revenue, €235.82 million, came from the United States.

TradingKey

This page from TradingKey provides a detailed quarterly and annual income statement for Indaptus Therapeutics Inc (INDP). It includes comprehensive financial data stretching back several years, covering total revenue, operating expenses, R&D expenses, operating profit, and net income. The page also offers FAQs on …

Danaher (DHR) Stock Tries To Steady After A Sharp Post Earnings Selloff

Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. Danaher (NYSE:DHR) shares saw a sharp post earnings selloff, with heavy trading activity highlighting strong investor reaction. Following the drop, the stock closed near its daily highs, …

Here's Why the Slump in Danaher Stock This Week Looks Like a Buying Opportunity

Shareholders in biotechnology, life sciences, and diagnostics solutions company Danaher (NYSE: DHR) have had an interesting week. Their stock crashed early in the week on the release of its second-quarter earnings, only to recover somewhat through the week and start Friday morning having declined …

AdaptHealth Corp. Revenue Breakdown – NASDAQ:AHCO

This article provides a revenue breakdown for AdaptHealth Corp. (NASDAQ: AHCO), highlighting that the company generated $3.24 billion USD last year. The "Sleep" segment was the top performer, contributing $1.38 billion USD, and the majority of the revenue, $3.24 billion USD, originated from the …

Adaptive Biotechnologies (ADPT) Stock May Be 22% Undervalued As Growth Hopes Build

Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. Adaptive Biotechnologies stock has delivered very strong total returns over the past three years, while its valuation signals are pulling in different directions, with the Discounted Cash …

Do Cardinal Health’s New Home-Health Deals Reshape the Bull Case for CAH?

Earlier this week, Cardinal Health announced agreements to acquire AdaptHealth's Diabetes Health business and Strive Medical for about US$360 million in cash, aiming to expand its at-Home Solutions footprint in diabetes management and urology. These moves, combined with management's previously raised profit guidance and …

Adaptive Biotechnologies (ADPT) After Loss Forecasts Improve Is The Rally Already Priced In

Adaptive Biotechnologies (ADPT) has shown strong recent stock momentum with significant returns over the past three months and year, driven by improved loss forecasts and revenue growth. While some analysts view the stock as overvalued at $22.31 compared to a $20.14 fair value based …

Adaptive Biotechnologies CSO Harlan Robins sells $10.78m in stock

Harlan S. Robins, CSO of Adaptive Biotechnologies Corp, sold approximately $10.78 million worth of company stock on July 21, 2026, after exercising stock options. These sales, conducted under a Rule 10b5-1 trading plan, occurred when the stock was near its 52-week high and followed …

Form 4 Adaptive Biotechnologies Corp For: 23 July By Investing.com

This article reports on a Form 4 filing for Adaptive Biotechnologies Corp (ADPT) for activity on July 23. It states that the information was published on July 24, 2026, at 01:06, and includes details about its stock performance, showing a slight increase of 0.22%. …

Adaptive Biotechnologies Corp (ADPT) CSO exercises options and sells 492,400 shares

Adaptive Biotechnologies Corp's Chief Scientific Officer, Harlan S. Robins, recently exercised stock options for 284,800 shares and subsequently sold 492,400 common shares. These transactions, executed under a Rule 10b5-1 trading plan, involved shares sold at weighted-average prices of $21.72 and $22.12. Following these trades, …

ADPT: Adaptive Biotechnologies Corp Latest Stock Price, Analysis, News and Trading Ideas

This page provides real-time stock information, analysis, news, and trading ideas for Adaptive Biotechnologies Corp (ADPT). It includes current stock price, market cap, volume, 52-week high/low, PE ratio, and upcoming earnings dates. The page also features recent news articles related to ADPT's earnings expectations …

Will Earnings Estimate Upgrades and a Smaller Projected Loss Change Adaptive Biotechnologies' (ADPT) Narrative?

Adaptive Biotechnologies (ADPT) recently received a Zacks Rank #2 (Buy) upgrade due to upward revisions in earnings estimates and expectations for a smaller projected loss and higher revenue for Q2 2026. This positive outlook is driven by improving business trends and strong performance in …

Danaher hebt EPS-Prognose nach Q2 an: Bioprocessing drückt, Aktie blei

Indaptus Therapeutics (INDP) Q3 2025 earnings summary

Indaptus Therapeutics (INDP) reported a Q3 2025 net loss of $3.0 million, with its lead candidate, Decoy20, in Phase 1 clinical trials for advanced solid tumors. The company completed the safety lead-in cohort for a combination study, showing tolerable safety and early stable disease …

Danaher Posts Mixed Q2 Results, Outlook for 2027 and Beyond Strengthened, RBC Says

Danaher's (DHR) Q2 results were mixed, with the lumpier part of its bioprocess consumables business PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have …

Can Danaher (DHR) Climb 32.39% to Reach the Level Wall Street Analysts Expect?

Danaher (DHR) closed the last trading session at $179.01, gaining 0% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of …

Don’t Quit on Danaher Stock After Horrific Earnings Reaction

To say Danaher Corp. had a downbeat reaction to earnings is an understatement. Danaher had its worst day in two decades on Tuesday after the life sciences and diagnostics company’s second-quarter earnings. Danaher expects core revenue (a metric that excludes things like currency and …

Adaptive Biotechnologies (ADPT) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Adaptive Biotechnologies (ADPT) is expected to report a year-over-year increase in earnings on higher revenues for the quarter ended June 2026, with an anticipated loss of $0.13 per share. The company currently holds a Zacks Rank #2, but its Earnings ESP of 0% suggests …

Danaher’s Q2 Earnings Call Shows Life Sciences at Its Best Quarter in Years

AdaptHealth Corp. (AHCO) Stock Analysis: Exploring a 24% Potential Upside in the Healthcare Sector

AdaptHealth Corp. (AHCO), a U.S.-based medical equipment distributor with a market cap of $1.49 billion, shows a potential upside of 24.09% according to analyst consensus, despite current profitability challenges. While the company faces a negative EPS and ROE, its robust free cash flow of …